Karen Tubridy, PharmD

    Karen Tubridy, PharmD
    Karen Tubridy, PharmD
    Senior Vice President, Chief Development Officer

    Karen Tubridy, PharmD joined Akebia as Senior Vice President, Chief Development Officer in November 2016. Prior to joining Akebia, Ms. Tubridy served as Chief Development Officer at Eleven Biotherapeutics. Prior to joining Eleven Biotherapeutics, Ms. Tubridy served as Senior Vice President, Clinical Development and Medical Affairs of Inspiration Biopharmaceuticals, Inc., a company that sold its hemophilia assets to Cangene Corporation and Baxter International in early 2013.

    Prior to joining Inspiration Biopharmaceuticals, Ms. Tubridy served as Executive Director, Clinical Operations and Regulatory Affairs, Translational Medicine of Alexion Pharmaceuticals, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals, and previously as Vice President of Clinical Operations and Regulatory Affairs of Taligen Therapeutics. Prior to that, Ms. Tubridy served as Vice President of Clinical Operations, Hemophilia at Biogen Idec, Inc. Ms. Tubridy received a B.S. and a Pharm.D. from the Massachusetts College of Pharmacy and Allied Health Sciences (MCPHS). Ms. Tubridy is a member of the Board of Trustees at MCPHS University.

    Gavin Malenfant

      Gavin Malenfant
      Gavin Malenfant
      Vice President, Corporate Operations
      Gavin Malenfant joined Akebia as Vice President of Corporate Operations in 2016. An industry veteran with over 25 years of experience in biotechnology. Mr. Malenfant has held leadership roles at both large and established organizations, as well as dynamic and rapidly-growing companies. He has provided operational leadership across multiple functions, including development, strategy and portfolio management. Mr. Malenfant has led product development teams, bringing commercially successful products to market and through commercial expansion phases. Mr. Malenfant most recently served as Head of Operations at Sarepta Therapeutics and was a member of the executive team, with accountability for manufacturing and a portfolio that led to an approved treatment for Duchenne Muscular Disease. Prior to Sarepta, Mr. Malenfant served as Head of Operations for R&D, Portfolio Strategy, and Program Management at Genzyme, a Sanofi Company. He received a B.S. in Biology from the University of Massachusetts Boston.

      Theresa McNeely

        Theresa McNeely
        Theresa McNeely
        Senior Vice President of Corporate Communications and Investor Relations
        Theresa McNeely is Senior Vice President, Corporate Communications and Investor Relations. Ms. McNeely has over 20 years of integrated corporate communications experience spanning investor relations, public relations, marketing communications, and patient advocacy in life sciences companies, including pharmaceutical and biotech, molecular diagnostics, tools, and service providers. She has counseled executive teams on communications strategies around key events, such as international product launches, clinical trial results, strategic redirection, executive transitions, financings, and regulatory decisions. Prior to Akebia, Ms. McNeely was Executive Vice President, Chief Communications Officer at OvaScience and before that, she was Vice President of Corporate Communications at Clinical Data, Inc., a company that was acquired by Forest Laboratories for $1.2 billion. Ms. McNeely has also held management positions at Millennium Pharmaceuticals, EXACT Sciences, and Pyrosequencing. Earlier in her career, Ms. McNeely worked on Wall Street for a boutique investment bank. She is a member of the Board of Directors for Women in Bio, and an Advisory Board member for Cramer Productions, a creative brand experience agency. Ms. McNeely received her B.S. in Business Administration from Providence College, and an M.S. in Business Communications and Healthcare Communications from Simmons College.
         
        Print Page
        Email Page
        Contact IR
        Email Alerts
        Tear Sheet